Table II.
Comparison between the intravenous sodium stibogluconate (IV SSG) and liposomal amphotericin B (L-AmB) treatment groups for Leishmania tropica cutaneous leishmaniasis
| Characteristics | L-AmB treatment | IV SSG treatment | p-value |
|---|---|---|---|
| Patients, n | 80 | 47 | NS |
| Male:female | 39:41 | 25:22 | NS |
| Age, years, mean | 17.5 | 23.9 | NS |
| Time to treatment (months) | 3 | 3 | NS |
| Number of lesions, mean | 3 | 2 | NS |
| Lesions in cartilaginous areas, n (%) | 23 (28.75) | 14 (29.78) | NS |
| Number of patients who failed previous treatments, n (%) | 42 (52.5) | 32 (68) | NS |
| Patients who switched from one systemic treatment to the other (L-AmB to IV SSG and vice versa), n (%) | 16 (20) | 3 (6) | NS |
| Number of patients who presented facial lesions/multiple lesions, n (%) | 38 (47.5) | 15 (32) | NS |
| Number of treatment days, mean | 6.3 | 18 | p< 0.05 |
| Patients who were completely cured, n (%) | 58/80 (72) | 33/47 (70) | NS |
| Patients who presented adverse effects, n (%) | 18/80 (22.5) | 20/47 (42.5) | p< 0.05 |
Complete cure: complete healing within 3 months; NS: non-significant.